Sol-Gel Technologies

SLGL

Market cap $119M

42.77 USD

+3.76

9.64%

At close Updated Dec 15, 3:59 PM EST

1 day

9.64%

5 days

-2.53%

1 month

18.81%

3 months

78.36%

6 months

507.53%

Year to date

319.31%

1 year

817.81%

5 years

-54.16%

10 years

-68.64%

About: Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Employees: 34

Healthcare Biotechnology